Merus

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Merus and other ETFs, options, and stocks.

About MRUS

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. 

CEO
Sven Ante Lundberg
CEOSven Ante Lundberg
Employees
260
Employees260
Headquarters
Utrecht, Utrecht
HeadquartersUtrecht, Utrecht
Founded
2003
Founded2003
Employees
260
Employees260

MRUS Key Statistics

Market cap
5.06B
Market cap5.06B
Price-Earnings ratio
-12.08
Price-Earnings ratio-12.08
Dividend yield
Dividend yield
Average volume
640.10K
Average volume640.10K
High today
$69.26
High today$69.26
Low today
$66.79
Low today$66.79
Open price
$68.49
Open price$68.49
Volume
634.80K
Volume634.80K
52 Week high
$70.65
52 Week high$70.65
52 Week low
$33.19
52 Week low$33.19

MRUS News

TipRanks 13h
Merus initiated with an Overweight at Barclays

Barclays initiated coverage of Merus (MRUS) with an Overweight rating and $112 price target The company’s Phase 3 clinical asset, petosemtamab, is being evaluat...

TipRanks 5d
Merus’s Oncology Potential and Financial Stability Justify Buy Rating

Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Merus and keeping the price target at $110.00. Elevate Your Investing Strategy: Take advanta...

Analyst ratings

100%

of 19 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own MRUS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.